115 related articles for article (PubMed ID: 38490327)
1. EPIC-0628 abrogates HOTAIR/EZH2 interaction and enhances the temozolomide efficacy via promoting ATF3 expression and inhibiting DNA damage repair in glioblastoma.
Yang E; Hong B; Wang Y; Wang Q; Zhao J; Cui X; Wu Y; Yang S; Su D; Liu X; Kang C
Cancer Lett; 2024 Apr; 588():216812. PubMed ID: 38490327
[TBL] [Abstract][Full Text] [Related]
2. A novel compound EPIC-0412 reverses temozolomide resistance via inhibiting DNA repair/MGMT in glioblastoma.
Zhao J; Yang S; Cui X; Wang Q; Yang E; Tong F; Hong B; Xiao M; Xin L; Xu C; Tan Y; Kang C
Neuro Oncol; 2023 May; 25(5):857-870. PubMed ID: 36272139
[TBL] [Abstract][Full Text] [Related]
3. EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT.
Xin L; Tan Y; Zhu Y; Cui X; Wang Q; Zhao J; Tian S; Xu C; Xiao M; Hong B; Xu J; Yuan X; Wang C; Kang C; Fang C
Neuro Oncol; 2023 Nov; 25(11):1976-1988. PubMed ID: 37279651
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
Wu Q; Berglund AE; Macaulay RJ; Etame AB
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894860
[TBL] [Abstract][Full Text] [Related]
5. BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression.
Tancredi A; Gusyatiner O; Bady P; Buri MC; Lomazzi R; Chiesi D; Messerer M; Hegi ME
Cell Death Dis; 2022 Dec; 13(12):1037. PubMed ID: 36513631
[TBL] [Abstract][Full Text] [Related]
6. NMDA receptor signaling induces the chemoresistance of temozolomide via upregulation of MGMT expression in glioblastoma cells.
Tsuji S; Nakamura S; Shoda K; Yamada T; Shimazawa M; Nakayama N; Iwama T; Hara H
J Neurooncol; 2022 Nov; 160(2):375-388. PubMed ID: 36308592
[TBL] [Abstract][Full Text] [Related]
7. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
Wu S; Li X; Gao F; de Groot JF; Koul D; Yung WKA
Neuro Oncol; 2021 Jun; 23(6):920-931. PubMed ID: 33433610
[TBL] [Abstract][Full Text] [Related]
8. EPIC-1042 as a potent PTRF/Cavin1-caveolin-1 interaction inhibitor to induce PARP1 autophagic degradation and suppress temozolomide efflux for glioblastoma.
Hong B; Yang E; Su D; Ju J; Cui X; Wang Q; Tong F; Zhao J; Yang S; Cheng C; Xin L; Xiao M; Yi K; Zhan Q; Ding Y; Xu H; Cui L; Kang C
Neuro Oncol; 2024 Jan; 26(1):100-114. PubMed ID: 37651725
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O
Jin L; Kiang KM; Cheng SY; Leung GK
Lab Invest; 2022 Feb; 102(2):194-203. PubMed ID: 34625658
[TBL] [Abstract][Full Text] [Related]
10. Lnc-TALC promotes O
Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
[TBL] [Abstract][Full Text] [Related]
11. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression.
Kohsaka S; Wang L; Yachi K; Mahabir R; Narita T; Itoh T; Tanino M; Kimura T; Nishihara H; Tanaka S
Mol Cancer Ther; 2012 Jun; 11(6):1289-99. PubMed ID: 22532597
[TBL] [Abstract][Full Text] [Related]
12. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.
Agnihotri S; Gajadhar AS; Ternamian C; Gorlia T; Diefes KL; Mischel PS; Kelly J; McGown G; Thorncroft M; Carlson BL; Sarkaria JN; Margison GP; Aldape K; Hawkins C; Hegi M; Guha A
J Clin Invest; 2012 Jan; 122(1):253-66. PubMed ID: 22156195
[TBL] [Abstract][Full Text] [Related]
13. Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma.
Gonzalez-Aponte MF; Damato AR; Trebucq LL; Simon T; Cárdenas-García SP; Cho K; Patti GJ; Golombek DA; Chiesa JJ; Rubin JB; Herzog ED
J Neurooncol; 2024 Feb; 166(3):419-430. PubMed ID: 38277015
[TBL] [Abstract][Full Text] [Related]
14. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC
Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841
[TBL] [Abstract][Full Text] [Related]
15. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465
[TBL] [Abstract][Full Text] [Related]
16. Specificity protein 1-modulated superoxide dismutase 2 enhances temozolomide resistance in glioblastoma, which is independent of O
Chang KY; Hsu TI; Hsu CC; Tsai SY; Liu JJ; Chou SW; Liu MS; Liou JP; Ko CY; Chen KY; Hung JJ; Chang WC; Chuang CK; Kao TJ; Chuang JY
Redox Biol; 2017 Oct; 13():655-664. PubMed ID: 28822335
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.
Kitange GJ; Mladek AC; Carlson BL; Schroeder MA; Pokorny JL; Cen L; Decker PA; Wu W; Lomberk GA; Gupta SK; Urrutia RA; Sarkaria JN
Clin Cancer Res; 2012 Aug; 18(15):4070-9. PubMed ID: 22675172
[TBL] [Abstract][Full Text] [Related]
18. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
Das A; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
J Neurol Sci; 2020 Nov; 418():117102. PubMed ID: 32866816
[TBL] [Abstract][Full Text] [Related]
19. MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma.
Gan T; Wang Y; Xie M; Wang Q; Zhao S; Wang P; Shi Q; Qian X; Miao F; Shen Z; Nie E
Cancer Res; 2022 Nov; 82(22):4234-4246. PubMed ID: 36112059
[TBL] [Abstract][Full Text] [Related]
20. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
Gupta SK; Kizilbash SH; Carlson BL; Mladek AC; Boakye-Agyeman F; Bakken KK; Pokorny JL; Schroeder MA; Decker PA; Cen L; Eckel-Passow JE; Sarkar G; Ballman KV; Reid JM; Jenkins RB; Verhaak RG; Sulman EP; Kitange GJ; Sarkaria JN
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26615020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]